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This report is based on the ‘Fibrosis: from bench to bedside’ symposium from the Keystone Symposia meeting
series, Keystone, Colorado, 23 to 28 March 2014. It was a fascinating symposium with high quality talks, workshops,
and well attended poster sessions.
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Fibrosis occurs in many organs upon injury or due to
genetic causes. The pathological bases of various fibrotic
diseases share considerable overlap with each other. An
inflammatory reaction is initiated to remove debris after
any kind of injury that results in cell death. In the
meantime, fibroblasts or other myofibroblast pre-cursors
are attracted to the site of injury where they start to
proliferate and secrete extracellular matrix (ECM).
After making a collagen-based scar, the myofibroblasts
will either become apoptotic or go into senescence.
During this symposium, various fibrotic processes were
discussed and both old and new players in fibrosis
were debated.Overview of selected talks
Harry Dietz (John Hopkins University School of
Medicine, USA) kicked off the symposium with an
interesting talk on scleroderma and systemic sclerosis
(SSc) and stiff skin syndrome (SSS). SSc is an autoimmune
disease in which the skin and other organs undergo
fibrotic changes. Harry Dietz used a fibrillin-1 knock-out
(KO) mouse model to study SSc and SSS. Fibrillin-1 KO
mice display the same phenotype as patients with
SSS, and the effects observed are regulated by integrin
signaling, because this phenotype is prevented by
integrin-modulating therapies. Fibrillin-1 is also known to
regulate TGFβ availability. (Chaudhry et al., Journal of
Cell biology, 2007) The group of Harry Dietz observed a* Correspondence: j.j.dehaan-4@umcutrecht.nl
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neutralizing antibody prevented fibrosis. A potential
regulator of the above mentioned fibrotic changes might
be microRNA29a (miR29a). Nelson Chau (Regulus
Therapeutics, San Diego, CA, USA) spoke more about
the emerging role of miRs in fibrosis. miR29 is
known to suppress ECM production. Furthermore,
miR29 is downregulated in patients with cirrhosis and
can therefore be used as a biomarker.
Judith Campisi (Buck Institute for Research on Aging,
Novato, CA, USA) continued with a talk on senescent
cells and their role in wound healing. Senescent cells
secrete senescence-associated secreted phenotype (SASP),
which includes numerous proteins, cytokines and matrix
metalloproteases (MMPs). In turn, SASP inhibits stem cell
proliferation. Transient presence of senescent cells is
required for proper wound healing. Eliminating senescent
cells results in highly fibrotic wounds. However, in
diseases associated with aging, it appears that senescent
cells are continuously present, which can lead to a
deleterious phenotype.
Currently, a lot of research is being conducted on
pericytes and their ability to transdifferentiate into
myofibroblasts. Jeremy Duffield (University of Washington,
USA) discovered a Foxd1 and PDGFRβ positive cell lineage
that can become myofibroblasts upon disease. Lucie
Peduto (Institut Pasteur, France) identified Gp38 +
ADAM12+ stromal cells that are present after injury.
ADAM12 is induced by TGFβ, and ADAM12 positive
pericytes infiltrate into the tissue upon injury and
disappear again when the injury is resolved. In the case of
chronic injury, the cells settle in the tissue but lose theirCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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less production of collagen after injury. Christian Göritz
(Karolinska Institutet, Sweden) talked about a subset of
pericytes that is involved in the repair of lesions of the
central nervous system called type A pericytes. When 80%
of type A pericytes are eliminated it will reduce scar
formation. Total depletion of type A pericytes results
in defective healing of the lesion.
An interesting talk by David Lagares (Massachusetts
General Hospital and Harvard Medical School, USA)
showed that tissue stiffness controls cell fate; fibroblasts
stay at 0.5 kPa, while myofibroblasts are present in
tissues with 25 kPA. Stiffness is not evenly distributed
within tissue, and they show that fibroblasts move
towards a stiffer environment. This process is called
durotaxis. In a stiffer environment, the fibroblasts will
transdifferentiate and start to express αSMA and secrete
ECM proteins. This process is called fibronucleation. It
creates a vicious cycle wherein an already stiff environment
attracts and activates fibroblasts.
Massimiliano Mellone (University of Southampton, UK)
described the role of DNA damage and DNA damage
response (DDR) pathways in myofibroblast transdiffer-
entiation. DNA damage leads to senescent fibroblasts and
that these senescent fibroblasts start to express αSMA.
TGFβ can activate DDR pathways and also induce
senescence. Furthermore, when you inhibit DDR pathway,
less myofibroblast transdifferentiation takes place. In
line with Massimiliano Mellone’s talk, Neetu Razdan
(Rutgers University, NJ, USA) discussed the role of
telomere dysfunction in αSMA expression. Prolonged
culturing of fibroblasts results in telomere shortening,
a naturally occurring phenomenon associated with
aging. Aging fibroblasts increase their αSMA expression.
Inhibiting telomere shortening by adding hTERT results
in reduced αSMA expression.
David Brenner (University of California, San Diego
Health Sciences, CA, USA) addressed the question of
where myofibroblasts go after repair in the injured liver.
He showed that 50% go into apoptosis while the other
50% turn into quiescent hepatic stellate cells (HSC), one
of the major pools for myofibroblasts in the liver. These
quiescent HSC are not the same as inactivated HSC, as
is shown by gene profiling. Additionally, quiescent HSC
seem to have a “memory for injury” as they are more rap-
idly reactivated than inactivated HSC.
Autophagy, a catabolic state the cell uses to maintain
viability under stress conditions, is involved in many
processes, including fibrosis. Monique Bernard (University
of Montreal Hospital Centre, Canada) linked autophagy to
myofibroblast transdifferentiation. In addition, Scott
Friedman (Mount Sinai School of Medicine, NY, USA)
explained that autophagy takes place in stellate cells upon
fibrotic stimuli. Deficiency of Atg7FP, an autophagy gene,leads to proliferation through Yes-Associated Protein
(YAP), a protein known to play a role in Hippo-signaling-
mediated activation of fibroblasts along with the protein
TAZ (Transcriptional coactivator with PFZ-binding motif).
James Pritchett (University of Manchester, UK) showed
that HSCs get activated when cultured on plastic and start
to express αSMA which leads to an increased expression
of YAP/TAZ. Knocking out YAP leads to a reduction of
αSMA expression and also to a reduction of Sox9, which is
known to regulate ECM expression during development.
Translation to the clinic
It is of great clinical importance to have a method for
early detection of fibrosis. As mentioned above, miR29
could be a new biomarker for liver fibrosis. In addition,
Timothy Radstake (University Medical Center Utrecht,
The Netherlands) presented data on the increased levels
of CXCL4 in SSC patients and how this can be a
novel biomarker, linking inflammation, endothelial dys-
function and fibrosis together. In addition to using fibrosis
for the detection of disease, it can also be targeted with
new medication. For example, Jeffrey Crosby (ISIS
Pharmaceuticals, Carlsbad, CA, USA) suggested using
antisense oligonucleotides for osteopontin (OPN) for
the treatment of idiopathic pulmonary fibrosis (IPF).
Using these oligonucleotides decreases OPN levels in
macrophages in the bronchoalveolar lavage from mice
and also reduces the damage in their lungs.
Elizabeth Trehu (Promedior, Inc., MA, USA) and Bernt
van den Blink (Erasmus MC, Netherlands) showed that
PRM-151, a recombinant form of Pentaxin-2 which
regulates monocyte differentiation and can decrease
fibrosis, increases forced vital capacity in patients with
IPF. Moreover, PRM-151 has already been shown to be
effective in animal models of lung, kidney, skin, and heart
fibrosis. Cédric Szyndralewiez (Genkyotex, Switserlands)
presented data on GKT137831, an NAPDH oxidase (NOX)
inhibitor. NOX1/4 plays an important role in liver fibrosis
by inducing apoptosis, myofibroblast differentiation, and
infiltration of macrophages. GKT137831 reduced fibrosis in
different liver fibrosis models by reducing the infiltration of
macrophages.
Dean Sheppard (University of California, CA, USA)
talked about the possibility of using the integrin αv
receptor on fibroblasts as a therapeutic target to prevent
fibrosis. He showed that deletion of fibroblast integrin
αv prevents fibrosis in a hepatic, renal, and pulmonary
model. Furthermore, a small molecule inhibitor against
αvβ1 inhibited the formation of fibrosis in bleomycin-
induced pulmonary fibrosis and CCl4-induced hepatic
fibrosis, suggesting that this is a promising new drug.
Benjamin Alman’s PhD student (Duke University, NC,
USA) presented data from a high throughput screen
which found nefopam to be a β-catenin inhibitor which
Figure 1 Highlights of the pathophysiology of fibrosis. Injury will lead to both activation of the immune system as well as activation of
pericytes and fibroblasts. Pericytes and fibroblasts can differentiate into myofibroblassts and many factors, listed here next to the arrow, have an
influence on this process. Myofibroblasts contribute to the secretion and remodeling of extracellular matrix, thereby inducing fibrosis. miR29a can
inhibit fibrosis. Inflammation also has a role in injury and subsequent fibrosis. Attracted leukocytes clear up debris and secrete inflammatory
molecules. A lot of factors can influence the inflammatory response, such as NOX-1/4 which is known to be involved in the influx of macrophages.
When the damage is repaired and a fibrotic scar is formed, myofibroblasts can either go into apoptosis or become quiescent fibroblasts. Biomarkers for
this fibrotic mechanism are listed in purple. Furthermore, there are current preclinical and clinical trials trying to inhibit fibrosis. The molecules and
drugs from these trials are shown in grey.
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decreased skin wound size in biopsy wounds in mice
and pig models.
Robert Lafyatis (Boston University School of Medicine,
MA, USA) found that fresolimumab, a thrombospondin
neutralizing antibody, improved the clinical Rodnan
score in SSc patients. On top of that, ADAM12 levels
predicted the improvement in thrombospondin levels
and might be a new biomarker for SSc.
Importantly, in 2014, two large, randomized, placebo
controlled Phase III trials were completed. Paul Noble
(Cedars-Sinai Medical Center, CA, USA) presented the
outcome of these trials: The ASCEND trial (pirfenidone)
and INPULSIS (nintedanib) study. Both pirfenidone and
nintedanib reduced the decline of forced vital capacity
over a 52-week period. These drugs show great potential
for patients with IPF.
This overview (summarized in Figure 1) discussed
just a small selection of all the great talks that were
presented at this symposium. The program of this
symposium was perfect to intermingle and to discuss
new and exciting data with each other. This was a
very successful symposium and many great ideas and
collaborations will certainly arise from this week.Competing interests
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